Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | MARS1 | P56192 | 3/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3559754 | 0.93 | SRD5A2 (0.41) | SRD5A2KDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL3555731 | 0.88 | CDC7 (0.46) | SRD5A2KDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL3556612 | 0.86 | KDM4E (0.47) | KDM4ESMN1; SMN2NPC1RAB9AHSD11B1 | |
| SCHEMBL476369 | 0.84 | SRD5A2 (0.45) | SRD5A2KDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL3553404 | 0.82 | CDC7 (0.45) | SRD5A2KDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL3556990 | 0.80 | GABRA2 (0.45) | KDM4ESMN1; SMN2NPC1RAB9APOLB | |
| SCHEMBL21350987 | 0.80 | MCL1 (0.40) | KDM4ESMN1; SMN2NPC1RAB9APOLB | |
| SCHEMBL12483972 | 0.79 | CHRNA7 (0.59) | SRD5A2POLBCHRNA7ALDH1A1RXFP1 | |
| SCHEMBL5095879 | 0.79 | CNR1 (0.63) | CNR1CNR2 | |
| SCHEMBL5109760 | 0.78 | CNR1 (0.42) | HSD11B1CNR1CNR2ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674821-B2 | N-[(4,5-diphenyl-3-alkyl-2-thienyl)methyl]amine [amide, sulfonamide, carbamate and urea) derivatives as cannabinoid CB1 receptor antagonists | SANOFI-AVENTIS (FR) | 2010-03-09 | — | — | US | disclosed |
| US-7462631-B2 | Thiophene-2-carboxamide derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2008-12-09 | — | — | US | disclosed |
| US-20070270470-A1 | N-[(4,5-DIPHENYL-3-ALKYL-2-THIENYL)METHYL]AMINE [AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | disclosed |
| EP-1833812-A1 | N-[(4, 5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL]AMINE (AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2007-09-19 | — | — | EP | disclosed |
| US-20060264470-A1 | Thiophene-2-carboxamide derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2006-11-23 | — | — | US | disclosed |
| EP-1678159-A2 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF AS CANNABINOID CB-1 RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006070106-A1 | N-[(4, 5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL] AMINE (AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2006-07-06 | — | — | WO | disclosed |
| WO-2005035488-A2 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF AS CANNABINOID CB-1 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264470-A1 | Thiophene-2-carboxamide derivatives, preparation and therapeutic application thereof | CNR1, CNR2, TPMT | SRD5A2 2053/4885KDM4E 691/4885SMN1; SMN2 1085/4885 |
| US-20070270470-A1 | N-[(4,5-DIPHENYL-3-ALKYL-2-THIENYL)METHYL]AMINE [AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | CNR1, CNR2, UTS2R | SRD5A2 2122/4885KDM4E 280/4885SMN1; SMN2 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.